Researchers at the University of Rochester Medical Center have initiated a comprehensive $27 million study aimed at improving treatment for heart failure patients. The six-year study will explore whether heart failure outcomes are better with medication alone or with the additional use of an implantable cardioverter defibrillator, a device designed to prevent sudden death in patients with known heart issues.
Dr. David Huang, director of cardiac electrophysiology at URMC, expressed that the study could potentially shift current treatment practices, which often favor the implantation of defibrillators. He noted, “We are thinking perhaps not every patient will need an implantable defibrillator. This is the landmark trial that’s going to help us find out and learn more about those possibilities.”
The study plans to enroll over 3,000 patients from 115 locations throughout the U.S. and Canada, making it a significant endeavor in the field of cardiac health.
FingerLakes1.com is the region’s leading all-digital news publication. The company was founded in 1998 and has been keeping residents informed for more than two decades. Have a lead? Send it to [email protected].